Evidence map›Paper›PMID 25004969›Full record

ArticleActa crystallographica. Section D, Biological crystallography2014

Structural and biochemical analyses of alanine racemase from the multidrug-resistant Clostridium difficile strain 630.

Oluwatoyin A Asojo, Sarah K Nelson, Sara Mootien, Yashang Lee, Wanderson C Rezende, Daniel A Hyman, Monica M Matsumoto, Scott Reiling, Alan Kelleher, Michel Ledizet and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Acta crystallographica. Section D, Biological crystallography, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 21 citations in OpenAlex.

  1. Ornithine racemase uses a catalytic cysteine.Biochimica et biophysica acta. Proteins and proteomics · 2026
    Article
  2. Review
  3. Draft genome assemblies of threemicroPublication biology · 2026
    Article
  4. Structure of pyridoxal 5'-phosphate-bound D-threonine aldolase from Chlamydomonas reinhardtii.Acta crystallographica. Section F, Structural biology communications · 2023
    Article
  5. Article
  6. Article
  7. AThe Journal of biological chemistry · 2017
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Oluwatoyin A AsojoNational School of Tropical Medicine, Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA.
Sarah K NelsonNational School of Tropical Medicine, Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA.
Sara MootienL2 Diagnostics LLC, 300 George Street, New Haven, CT 06511, USA.
Yashang LeeL2 Diagnostics LLC, 300 George Street, New Haven, CT 06511, USA.
Wanderson C RezendeNational School of Tropical Medicine, Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA.
Daniel A HymanNational School of Tropical Medicine, Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA.
Monica M MatsumotoNational School of Tropical Medicine, Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA.
Scott ReilingPathology and Microbiology Department, University of Nebraska Medical Center, Omaha, NE 68105, USA.
Alan KelleherNational School of Tropical Medicine, Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA.
Michel LedizetL2 Diagnostics LLC, 300 George Street, New Haven, CT 06511, USA.
Raymond A KoskiL2 Diagnostics LLC, 300 George Street, New Haven, CT 06511, USA.
Karen G AnthonyL2 Diagnostics LLC, 300 George Street, New Haven, CT 06511, USA.
Baylor College of Medicine · USUniversity of Nebraska Medical Center · US

Funding

Broad-Spectrum Antimicrobials Targeting the D-Alanine PathwayU01AI082081 · NIAID · L2 DIAGNOSTICS, LLC · PI ANTHONY, KAREN G. · 2009 to 2013
$7.0M
NIAID NIH HHS 5U01AI082081NIAID NIH HHS U01 AI082081
6 · The paper itself

Abstract

Clostridium difficile, a Gram-positive, spore-forming anaerobic bacterium, is the leading cause of infectious diarrhea among hospitalized patients. C. difficile is frequently associated with antibiotic treatment, and causes diseases ranging from antibiotic-associated diarrhea to life-threatening pseudomembranous colitis. The severity of C. difficile infections is exacerbated by the emergence of hypervirulent and multidrug-resistant strains, which are difficult to treat and are often associated with increased mortality rates. Alanine racemase (Alr) is a pyridoxal-5'-phosphate (PLP)-dependent enzyme that catalyzes the reversible racemization of L- and D-alanine. Since D-alanine is an essential component of the bacterial cell-wall peptidoglycan, and there are no known Alr homologs in humans, this enzyme is being tested as an antibiotic target. Cycloserine is an antibiotic that inhibits Alr. In this study, the catalytic properties and crystal structures of recombinant Alr from the virulent and multidrug-resistant C. difficile strain 630 are presented. Three crystal structures of C. difficile Alr (CdAlr), corresponding to the complex with PLP, the complex with cycloserine and a K271T mutant form of the enzyme with bound PLP, are presented. The structures are prototypical Alr homodimers with two active sites in which the cofactor PLP and cycloserine are localized. Kinetic analyses reveal that the K271T mutant CdAlr has the highest catalytic constants reported to date for any Alr. Additional studies are needed to identify the basis for the high catalytic activity. The structural and activity data presented are first steps towards using CdAlr for the development of structure-based therapeutics for C. difficile infections.

Indexed as

Drug Resistance, Multiple, BacterialAlanine RacemaseAmino Acid SequenceChromatography, GelClostridioides difficileCrystallography, X-RayDimerizationMolecular Sequence DataProtein ConformationRecombinant ProteinsSequence Homology, Amino AcidAlanine RacemaseRecombinant Proteinsalanine racemaseClostridium difficile infectioncycloserinedrug developmentmultidrug resistancenosocomial infectionspyridoxal-5′-phosphatestructure-based drug design

Identifiers

PMID25004969
PMCPMC4089486
OpenAlexW2068021689

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.